PROM1 and neoplasm: The development of CAR-based therapy for targeting melanoma CSC markers, such as CD133, ALDH1, and GD2, especially the strategy for dual- and multitargeting of different tumor antigens by CARs [143], holds significant promise for treating aggressive and therapy-resistant cancers.